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Abstract: Survival predictions are currently determined on the basis of NRAS/BRAF mutations,
even though TERT promoter mutations have been recently associated with a poor prognosis in
stage I-II melanomas. Usually, it is not recommended to perform a mutational test on primary
melanoma, as the results do not always reflect the mutational status of metastases. In particular,
trunk melanomas have been reported to have an unfavourable prognosis. A series of 105 advanced
melanoma patients were analysed by TERT promoter Sanger sequencing. Univariate/multivariate
binary logistic regression models were performed using progression to a visceral site as the dependent
variable and patient/tumour characteristics as covariates. Performance of the model was assessed
in an external independent primary melanoma patients’ dataset. Male gender (odds ratio (OR),
344; 95% CI, 1.12–10.6; p = 0.031), AJCC (American Joint Committee on Cancer) classification (OR,
022; 95% CI, 0.07–0.67; p = 0.008), SLNB (Sentinel Lymph Node Biopsy) status (OR, 3.05; 95% CI,
1.06–8.78; p = 0.039) and TERT-mutated trunk lesions (OR, 3.78; 95% CI, 1.35–10.6; p = 0.011) were
significantly associated with the risk of developing a visceral spreading as first site of progression
using multivariate logistic regression analysis. These results were confirmed in the external validation
control group. Therefore, in trunk primary melanomas, due to their high risk of progression to visceral
sites, we encourage somatic TERT mutation analysis at diagnosis to identify those patients who
would potentially benefit from a more intensive follow-up protocol and a prompt initiation of therapy.
Keywords: TERT promoter; trunk; melanoma; visceral metastases
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1. Introduction
Genetic testing for targetable somatic mutations is considered mandatory by the European
Guidelines in the context of diagnosis, treatment and follow-up of cutaneous melanomas in patients
with advanced disease (unresectable stage III or stage IV), and highly recommended in high-risk
resected disease (stage IIC or stages IIIB–IIIC) [1]. In BRAF wild type tumours, alternative mutations
occurring at NRAS and c-Kit genes must be tested. Tumour heterogeneity in advanced stage melanoma
has important implications for molecular testing and treatment. Mutation load increases with
progression and unique patterns of genetic changes termed ‘evolutionary trajectories’, have been
observed in different melanoma subtypes [2,3]. In particular, as reported by Shain et al., melanomas
mutated at NRAS or BRAF (V600K or K601E) are more commonly associated with intermediate lesions
or melanomas in situ that have already accumulated other pathogenic mutations [2]. In clinical practice,
it is not recommended to test for BRAF mutations in primary cutaneous melanoma unless these data
are required to guide systemic therapy in advanced stages. Several studies suggest that detection
of a wild type BRAF (B-Raf proto-oncogene) in the primary tumour may not necessarily reflect the
BRAF mutation status of metastases [4,5]. Therefore, clinicians should consider repeating the test in
the most recent metastasis (if available) to determine the BRAF mutation status [4]. In daily clinical
practice, patients often come to our attention with advanced stages, progressing either after a positive
or a negative sentinel lymph node (SLN), or directly from a primary to a distant metastatic site [6,7].
Moreover, when metastasis sampling is not feasible due to the anatomical site or to other patient
clinical comorbidities, mutation analysis is performed on the primary lesion.
Recently, Nagore et al. provided preliminary evidence that in stage I/II melanoma patients TERT
promoter status in combination with BRAF/NRAS mutations can be used to identify patients at risk
of aggressive disease and the possibility of further prognostic refinement by assessing the rs2853669
polymorphism within TERT promoter [8].
Based on these assumptions, we analysed a consecutive series of patients with advanced
melanoma who underwent mutational testing preliminary to treatment with specific targeted therapies
at the tertiary Dermo-Oncologic Centre of our Hospital. In particular, in this study we retrospectively
analysed advanced melanomas that had directly progressed from stage IB/II AJCC (American Joint
Committee on Cancer) 2017 [9], whose mutational status of BRAF, KRAS, NRAS and PIK3CA genes
had already been tested. In these specimens, TERT promoter status and its rs2853669 single nucleotide
variant (SNV) were then investigated to ascertain associations between the molecular profile and the
pattern of progression with the aim of determining the prognostic value of TERT promoter mutations
in a subset of IB/II stage melanoma patients with poorer prognosis.
2. Results
2.1. Clinical Characteristics
A total of 105 patients (Table 1) satisfied the inclusion criteria of our study protocol. The average
Breslow thickness of primary melanomas was 3.7 mm ± 2.8, while the median follow-up after
melanoma diagnosis was 5.8 years (3.2–12.2). The median age at diagnosis was 70 years (range
22–88). Overall, 63 patients (60.0%) were male. The majority of melanomas appeared on the trunk
(n = 41, 39.1%). The Nodular melanoma (NM) histotype was observed in 16 out of 105 (15.2%).
Ulceration was present in 49 out of 105 patients (46.7%). SLNB (Sentinel Lymph Node Biopsy) was
performed in 41 out of 105 patients (39.0%). In the remaining 64 patients SLNB was not performed: in
27 patients after collegial decision, in six patients whose melanoma thickness was above 4 mm and
between 0.8–1 mm respectively (SLNB not indicated, ante 2018), in 16 patients older than 75 years, in
seven patients with other comorbidities, in two patients whose SLN were not traced, in four patients
refusing the procedure and in two patients diagnosed ante-SLNB technique.
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Table 1. Clinical characteristics based on the pattern of first relapse.
Patients
Pattern of First Relapse
Total (105) Regional (A)(58; 55.2%)
Regional + Distant
(B) (15; 14.3%)
Visceral Only (C)
(32; 30.5%) p **
Median time to relapse
(years. 25th–75th) 1.9 (0.7–3.8) 1.8 (0.7–3.8) 1.8 (0.5–5.7) 2.2 (0.8–3.8) 0.956
Gender
F 42 (40%) 27 (70.5%) 8 (53.3%) 7 (21.9%) 0.038
(C vs. A 0.06)M 63 (60%) 31 (29.5%) 7 (46.7%) 25 (78.1%)
Age at diagnosis Median (interval) 70 (22–88) 71 (28–87) 72 (34–86) 66 (22–88) 0.249
Primary site
Head/neck a 16 (15.2%) 8 (13.8%) 5 (33.3%) 3 (9.4%)
0.030
(d vs. b 0.021)Trunk
b 41 (39.1%) 16 (27.6%) 5 (33.3%) 20 (62.5%)
Upper extremities c 12 (11.4%) 8 (13.8%) 2 (13.4%) 2 (6.2%)
Lower extremities d 36 (34.3%) 26 (44.8%) 3 (20.0%) 7 (21.9%)
Histotype Nodular 16 (15.2%) 8 (13.8%) 4 (26.7%) 4 (12.5%) 0.407
Other 89 (84.8%) 50 (86.2%) 11 (73.3%) 28 (87.5%)
Breslow mm ± DS 3.7 ± 2.8 4.0 ± 2.8 4.8 ± 2.8 2.7 ± 1.9 0.005(C vs. B p = 0.04)
Ulceration
Absent 59 (56.2%) 33 (56.9%) 4 (26.7%) 22 (68.7%) 0.025
(C vs. B p = 0.02)Present 46 (43.8%) 25 (43.1%) 11 (73.3%) 10 (38.3%)
SLNB
Not performed 64 (60.9%) 39 (67.2%) 11 (73.3%) 14 (43.7%)
0.052
Negative 41 (39.1%) 19 (32.8%) 4 (26.7%) 18 (56.2%)
AJCC 2017
IB 24 (22.9%) 9 (15.5%) 2 (13.3%) 13 (40.6%) <0.001
(C vs. A p = 0.03
C vs. B p = 0.12)
IIA 31 (29.5%) 19 (32.8%) 5 (33.3%) 7 (21.9%)
IIB 29 (27.6%) 18 (31.0%) 0 (0.0%) 11 (34.4%)
IIC 21 (20.0%) 12 (20.7%) 8 (53.4%) 1 (3.1%)
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Table 1. Cont.
Patients
Pattern of First Relapse
Total (105) Regional (A)(58; 55.2%)
Regional + Distant
(B) (15; 14.3%)
Visceral Only (C)
(32; 30.5%) p **
Mutational status
(Sequenom)
WT* 32 (30.5%) 15 (25.9%) 6 (40.0%) 11 (34.4%)
0.470
BRAF MUT 44 (41.9%) 25 (43.1%) 8 (53.3%) 11 (34.4%)
NRAS MUT 27 (25.7%) 17 (29.3%) 1 (6.7%) 9 (28.1%)
KRAS MUT 1 (0.9%) 1 (1.7%) 0 (0%) 0 (0%)
PIK3CA MUT 1 (0.9%) 0 (0%) 0 (0%) 1 (3.1%)
Mutational status site
Primary 42 (40.0%) 14 (24.1%) 8 (53.4%) 20 (62.5%) <0.001
(B vs. A, C vs. B
<0.001)
Regional mts 46 (43.8%) 39 (67.3%) 5 (33.3%) 2 (6.3%)
Distant mts 17 (16.2%) 5 (8.6%) 2 (13.3%) 10 (31.2%)
TERT promoter
mutations
WT 31 (29.5%) 20 (34.5%) 4 (26.7%) 7 (21.9%)
0.440
−146 or −124 C > T 74 (70.5%) 38 (65.5%) 11 (73.3%) 25 (78.1%)
TERT rs2853669
Absent 51 (48.6%) 28 (48.3%) 8 (53.3%) 15 (46.9%)
0.916
Present 54 (51.4%) 30 (51.7%) 7 (46.7%) 17 (53.1%)
TERT/Trunk site
WT/no trunk a 24 (22.9%) 15 (25.9%) 3 (20.0%) 6 (18.8%)
0.0045
(D vs. B p = 0.01)
−146 or −124 C > T
mut/no trunk b 40 (38.1%) 27 (46.5%) 7 (46.7%) 6 (18.8%)
WT/trunk c 7 (6.7%) 5 (8.6%) 1 (6.7%) 1 (3.1%)
−146 or −124 C > T
mut/trunk d 34 (32.4%) 11 (18.9%) 4 (26.7%) 19 (59.4%)
* One case D816H c-kit mutated; ** Bonferroni correction has been reported when significative. a: Head/neck; b: Trunk; c: Upper extremities; d: Lower extremities Bonferroni
correction groups.
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Metastases included in the study appeared after median follow-up of 1.9 years from primary
melanoma diagnosis (0.7–3.8). Fifty-eight patients developed regional metastases only (24 skin,
29 lymph nodes, and five skin and lymph nodes), 15 had concomitant regional and distant metastases
and 32 exhibited visceral metastases as first and unique sites of relapse. In detail, among the latter with
visceral metastases, 19 patients had a single site of involvement (eight lung, seven brain, two liver, one
spleen and one peritoneum), nine patients exhibited two metastatic sites and four patients had more
than two sites involved. The visceral pattern of relapse seems to be related to the trunk site of primary
melanoma but not with NM histotype. No differences in median time to relapse were observed to be
associated with the site of disease relapse (log-rank test p = 0.9564) (Table 1, Figure 1).Cancers 2019, 11, x FOR PEER REVIEW 6 of 14 
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Figure 1. Time to relapse based on type of site of disease relapse (log-rank test p = 0.9564). 
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2.2. Mutational Assessment
Mutational assessment to guide targeted therapy was performed in 42 primary lesions: 20 patients
(48.8%) with visceral metastases were surgically inaccessible, 8 had regional lymph node and visceral
metastases without indications for lymph node dissection and 14 had only regional metastases that
did not undergo surgical resection due to other clinical conditions (older age, comorbidities). In
the remaining patients, mutational status was assessed on the most recently available metastases:
46 regional metastases and 17 visceral metastases, respectively (Table 1). All patients were tested
with Sequenom (32 WT (Wild-Type), 44 BRAF-mutated, 27 NRAS-mutated, 1 KRAS-mutated and
1 PIK3CA-mutated), among these 4 out of 6 acral melanomas (4 WT, 1 NRAS-mutated and 1
BRAF-mutated) were also tested for KIT mutations: only 1 out of 4 WT lesions carried a D816H
KIT mutation. Moreover, 74 out of 105 samples showed the most frequent TERT promoter mutations:
−124 C > T or −146 C > T (minor mutations were reported in Table 2).
No association between BRAF, KRAS, NRAS, PIK3CA and TERT promoter mutations or rs2853669
was observed with first relapse site. Conversely, the TERT promoter mutation detected in any tested
site was associated with the trunk site of primary lesion (34 out 41 patients, 82.9%) (Tables 1 and 3).
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Table 2. TERT promoter mutations details based on pattern of first relapse.
Patients Total(105)
Other Site of Progression
(73; 55.4%)
Only Visceral
(32; 44.6%)
TERT Promoter
mutations
−124 C > T 37 24 (32.9%) 13 (40.6%)
−146 C > T 37 25 (34.2%) 12 (37.5%)
−57 A > C 2 2 (2.7%) 0 (0%)
−125_124 CC > TT 2 2 (2.7%) 0 (0%)
−139_138 CC > TT 2 1 (1.4%) 1 (1.4%)
WT 25 19 (26.0%) 6 (18.8%)
Table 3. Clinical characteristics based on TERT promoter mutations.
Patients
TERT Promoter
p **
Total WT or MinorMutations (31)
−146 or−124
C>T Mutation (74)
Gender
F 42 (40%) 13 (41.9%) 29 (39.2%)
0.793
M 63 (60%) 18 (58.1%) 45 (60.8%)
Age at
diagnosis Median (interval) 70 (22–88) 72 (22–85) 68 (26–88) 0.950
Primary site
Head/neck a 16 (15.2%) 5 (16.1%) 11 (14.9%) 0.010
(d vs. b 0.014
c vs. d 0.010)
Trunk b 41 (39.0%) 7 (22.6%) 34 (45.9%)
Upper extremities c 12 (11.4%) 1 (3.2%) 11 (14.9%)
Lower extremities
d 36 (34.3%) 18 (58.1%) 18 (24.3%)
Histotype Nodular 16 (15.2%) 3 (9.7%) 13 (17.6%) 0.305
Other 89 (84.8%) 28 (90.3%) 61 (82.4%)
Breslow mm ± DS 3.7 ± 2.8 4.1 ± 3.2 3.6 ± 2.6 0.362
Ulceration
Absent 59 (56.2%) 16 (51.6%) 43 (58.1%)
0.541
Present 46 (43.8%) 15 (48.4%) 31 (41.9%)
SLNB
Not performed 64 (60.9%) 19 (61.3%) 45 (60.8%)
0.963
Negative 41 (39.1%) 12 (38.7%) 29 (39.2%)
AJCC 2017
IB 24 (22.8%) 3 (9.7%) 21 (28.4%)
0.175IIA 31 (29.5%) 12 (38.7%) 19 (25.7%)
IIB 29 (27.6%) 10 (32.3%) 19 (25.7%)
IIC 21 (20.0%) 6 (19.3%) 15 (20.3%)
Mutational
status
(Sequenom)
WT * 32 (30.5%) 12 (38.7%) 20 (27.0%)
0.187
BRAF MUT 44 (41.9%) 8 (25.8%) 36 (48.7%)
NRAS MUT 27 (25.7%) 11 (35.5%) 16 (21.6%)
KRAS MUT 1 (0.95%) 0 (0%) 1 (1.35%)
PIK3CA MUT 1 (0.95%) 0 (0%) 1 (1.35%)
Mutational
status site
Primary 42 (40%) 13 (41.9%) 29 (39.2%)
0.496Regional mts 46 (43.8%) 15 (48.4%) 31 (41.9%)
Distant mts 17 (16.2%) 3 (9.7%) 14 (18.9%)
TERT rs2853669
Absent 51 (48.6%) 16 (51.6%) 35 (47.3%)
0.687
Present 54 (51.4%) 15 (48.4%) 39 (52.7%)
* One case D816H KIT mutated, ** Bonferroni corrections were reported when significative. a: Head/neck; b: Trunk;
c: Upper extremities; d: Lower extremities Bonferroni correction groups.
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In consideration of the limited sample size due to a real-life study setting, the two most represented
mutations (−124 C > T and −146 C > T) have been combined together for the analyses. Indeed, to
analyse the variants separately it would have been necessary a minimum of 230 melanoma cases
in order to detect a significant 5% difference in outcomes between −124 and −146 TERT mutations
according to a power calculation analysis using visceral specific recurrence as the primary end point
with a 80% power and a two-sided α = 0.05 test. Moreover, we have not stratified patients according to
−57A > C because only two cases were observed (Table 2).
2.3. Association Between Trunk Site and TERT Mutation
Considered that visceral spread seemed to be associated with a trunk primary melanoma and
that the TERT promoter mutation frequently occurred in patients whose primary lesion developed
at this site, we analysed the progression pattern by evaluating the association between the trunk site
and the TERT promoter mutation. In the group in which the mutational status was performed on the
primary lesion, data showed that 12 out of 18 cases (66.7%) with a −124 or −146 C > T mutation and
the primary site on the trunk had developed visceral spreading as the first site of progression.
At univariate analysis (Table 4), logistic regression highlighted a significant association between
the TERT promoter mutation and trunk site with visceral spreading (OR 5.33, CI 1.02–27.7) when
considering cases in which only the primary lesion was analysed. This finding was consistent even
when considering the cases in which both the primary lesion and the metastasis were analysed. In
summary, 19 out of 34 patients (55.9%) who had a TERT promoter mutation in the primary or metastatic
lesion associated with a primary melanoma trunk site, developed visceral spreading as the first site of
progression (OR 3.64, CI 1.14–11.66). The other variables associated with visceral spreading were male
gender, trunk site, performed SLNB procedure (thus correctly staged) and also lower AJCC stage.
Table 4. Univariate logistic regression.
Variable
Only Visceral Site
OR CI p
Age (linear) 0.98 0.95–1.00 0.141
Gender (F vs. M) 3.28 1.26–8.55 0.015
Breslow (linear) 0.74 0.57–0.94 0.015
Ulceration (absent vs. present) 0.46 0.19–1.12 0.089
AJCC 2017 (IB vs. IIA, IIB, IIC) 0.26 0.09–0.67 0.006
NM versus other histotype 0.72 0.21–2.45 0.606
Trunk vs. other site 3.41 1.43–8.11 0.006
Mutational status (Mut vs. WT) 0.77 0.32–1.87 0.566
SLNB status (negative vs. not performed) 2.79 1.18–6.57 0.019
−146 or −124 C > T TERT promoter mutations 1.75 0.66–4.61 0.259
TERT rs2853669 1.10 0.48–2.53 0.818
TERT status and trunk
association only in
primary lesions
WT/no trunk 1
−146 or −124 C > T mut/no trunk 1.52 0.25–9.29 0.648
WT/trunk 2.67 0.12–57.6 0.532
−146 or −124 C > T mut/trunk 5.33 1.02–27.7 0.047
TERT status and trunk
association in all
WT/no trunk 1
−146 or −124 C > T mut/no trunk 0.68 0.21–2.28 0.538
WT/trunk 0.50 0.05–5.03 0.556
−146 or −124 C > T mut/trunk 3.64 1.14–11.66 0.029
TERT mut + trunk site vs. other only in primary 4.00 1.09–14.62 0.036
TERT mut + trunk site vs. other 4.78 1.93–11.8 0.001
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Multivariate logistic regression analyses (Table 5) confirmed the significant association between
TERT promoter mutation and trunk site with visceral spreading also when adjusting for age, gender,
AJCC staging and SLNB, suggesting that preferential visceral spreading as the first site of progression
is related to TERT-mutated lesions in patients whose primary lesion is located on the trunk. Moreover,
the Hosmer–Lemeshow goodness-of-fit statistics (p-value = 0.5460) indicated that the model adequately
describes the data.
Table 5. Multivariate logistic regression.
Multivariable
Only Visceral Site
OR CI p
Age (linear) 0.99 0.96–1.03 0.684
Gender (F vs. M) 3.44 1.12–10.6 0.031
AJCC 2017 (IB vs. IIA, IIB, IIC) 0.22 0.07–0.67 0.008
SLNB status (negative vs. not performed) 3.05 1.06–8.78 0.039
TERT mut + trunk site vs. other 3.78 1.35–10.6 0.011
2.4. Validation in the Independent Cohort of the Instituto Valenciano de Oncologia Data Set
To test the reproducibility of the association between TERT promoter mutation in trunk site
with visceral metastases as first site of progression, we investigated its performance in data collected
from 83 stage II primary melanoma patients all progressed to a metastatic stage recruited in Valencia
by the Instituto Valenciano de Oncologia (Prof. E Nagore) (Table 6). Data on the variables used to
define association were extracted from dataset and equally classified as for the pooled data described
above. Multivariate logistic regression analyses performed in the Valencia dataset (Table 7) confirmed
the significant association between TERT promoter mutation and trunk site with visceral spreading
(OR 4.81, CI 1.01–22.9; Hosmer–Lemeshow goodness-of-fit statistics, p = 0.8986).
Table 6. Clinical characteristics of Istituto Valenciano de Oncologia dataset based on pattern of
first relapse.
Patients Total(83)
Other Site of
Progression
(46; 55.4%)
Only Visceral
(37; 44.6%) p
Gender
F 31 (37.3%) 21 (45.6%) 10 (27.0%)
0.081
M 52 (62.7%) 25 (54.4%) 27 (73.0%)
Age at
diagnosis Median (interval) 64 (21–87) 65 (26–87) 60 (21–84) 0.404
Primary site
Head/neck 22 (26.5%) 9 (19.6%) 13 (35.1%)
0.059Trunk 25 (30.1%) 5 (44.0%) 20 (37.8%)
Upper extremities 9 (10.8%) 2 (13.0%) 2 (8.1%)
Lower extremities 27 (32.5%) 3 (43.5%) 7 (18.9%)
SLNB
Not performed 18 (21.7%) 10 (21.7%) 8 (21.6%)
0.990
Negative 65 (78.3%) 4 (78.3%) 18 (78.4%)
AJCC 2017
IB 24 (28.9%) 15 (32.6%) 9 (24.3%)
0.408
IIA, IIB, IIC 59 (71.1%) 31 (67.4%) 28 (75.7%)
TERT/Trunk
site
WT/no trunk 34 (40.9%) 20 (43.5%) 14(37.8%)
0.149−146 or −124 C > T mut/no trunk 24 (28.9%) 15 (32.6%) 9 (24.3%)
WT/trunk 13 (15.7%) 8 (17.4%) 5 (13.5%)
−146 or −124 C > T mut/trunk 12 (14.5%) 3 (6.5%) 9 (24.3%)
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Table 7. Multivariate logistic regression in Istituto Valenciano de Oncologia dataset.
Multivariable Logistic Regression Only Visceral Site
OR CI p
Age (linear) 0.99 0.97–1.02 0.856
Gender (F vs. M) 2.49 0.92–6.70 0.071
AJCC 2017 (IB vs. IIA, IIB, IIC) 0.99 0.32–3.07 0.997
SLNB status (negative vs. not performed) 1.26 0.41–3.86 0.682
TERT mut + trunk site vs. other 4.80 1.01–22.9 0.049
3. Discussion
Our experience in daily practice highlights that mutational status assessment of progressed
Stage IB/II melanoma patients is conditioned not only by the progression site, but also by patient
comorbidities that can influence surgical management. All these conditions affect the available tissue
type for molecular testing. In particular, disease progression in not surgically accessible anatomical
sites often (40% of cases) makes it necessary to use the primary lesion instead of the most recently
developed distant metastasis. Guidelines for follow-up of stage I–II patients (correctly staged through
SLNB or not) differ around centres and usually do not envisage serial screening of visceral sites in the
low risk of progression group [10,11] although many patients with an intermediate Breslow thickness
melanoma risk progress directly to a visceral site [6,12]. In stage IB/II patients, a more individualised
follow-up taking into account the risk factors associated with relapse in visceral sites, which include
male gender, trunk site and different SLNB proposal and management [6,7,13–16], would be desirable.
In our consecutive case series of metastatic melanomas, stage IB was more commonly associated
with visceral site than higher stages (IIA, IIB and IIC). At the moment, no reliable biomarkers except
SLN status have proven to be associated with the real risk of primary melanoma progression, and no
information can be specifically ascertained based upon the hypothesis (not supported by biological
data, so far) of a predisposition of trunk melanoma to progress to visceral sites [14,17].
In this context, new markers are needed for discriminating patients at higher risk of visceral
relapse. Despite the heterogeneity of our cohort, our results showed that the TERT promoter
mutations in primary trunk melanoma are related to visceral spreading as the first site of progression,
independently of SLNB management and AJCC stage, thus suggesting that −124 or −146 C > T
mutations may be considered as risk factors of visceral spreading in trunk lesions. This finding has
been validated in an independent Valencia cohort of primary melanoma patients all progressed to a
metastatic phase, confirming the reliability of this association.
Furthermore, the association between TERT promoter mutations and trunk site is supported
by evidence that melanomas occurring in intermittently sun-exposed skin as trunk site displayed
an increased prevalence of TERT promoter mutations compared with melanomas occurring in
sun-protected areas [18].
It is well known that TERT mutations enhance the expression of the TERT gene by creating
de novo binding motifs for different transcription factors [19] involved in tumorigenic mechanisms,
but its prognostic role is debated. Several authors have reported a prognostic significance of TERT
promoter mutations in primary melanomas [18,20,21], whereas other studies [22,23] found no impact in
primary and metastatic melanoma. In our experience, TERT promoter mutations have been identified
both in primary and metastatic visceral lesions of patients with a trunk primary. These data are in
agreement with Shain et al. [2], who also identified TERT promoter mutations in intermediate lesions
and melanomas in situ, in addition to invasive and metastatic melanomas, thus confirming that TERT
mutations are selected in an early stage of the neoplastic progression and maintained during the entire
metastatic process [2], in variance with other mutations like BRAF which can show a discordance
between primary and metastatic tumours in 11% of cases [4,24].
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A meta-analysis indicates that TERT promoter mutations are associated with patient age, gender and
distant metastasis in individuals with cancers [25]. In particular promoter mutations were found to be
independent risk factors for distant metastases in thyroid carcinoma. Moreover, in thyroid carcinoma TERT
inhibition has been related to reduced cell growth, invasion, migration and angiogenesis [26,27]. Trunk
melanomas have been associated in many studies to visceral involvement [15–17], TERT promoter
mutation can be the biological explanation of trunk melanoma ability to skip regional metastases by
promoting visceral spreading.
Our data reflect daily clinical practice, which often deviates from optimal conditions. We are
aware of the limitations of this study:
(1) The cohort is not homogeneous in term of SLN management, but in order to keep this fact in
consideration, the model had been adjusted for this feature (SLNB performed vs. not performed). The
association between visceral progression and TERT promoter mutation in trunk site patients should be
considered even more reliable due to the fact that it maintained its prognostic role after this adjustment.
(2) The relative low sample of our study did not allow us to perform stratification on the basis of
TERT promoter mutation variant.
(3) It was not possible to confirm the preservation of TERT promoter mutation along the
disease course (from primary tumour to metastases in the same patient) due to incomplete
specimen availability.
(4) Conventional Polymerase Chain Reaction (PCR) followed by Sanger sequencing can
underestimate the wild type/mutated allele ratio of TERT promoter compared to other methods [28].
However, our results and the external validation in a group of progressed primary melanomas
support the previously reported finding of a worse outcome in TERT-mutated trunk melanomas.
Therefore, we encourage TERT promoter mutation analysis at diagnosis in the primary melanomas of
the trunk since their progression will likely occur in a visceral site in the majority of cases and patients
would potentially benefit from early detection and prompt treatment.
4. Material and Methods
4.1. Patients
A series of 105 progressed stage IB/II AJCC melanoma patients (24 stage IB, 31 stage IIA, 29 stage
IIB and 21 stage IIC) with complete clinicopathological annotated features underwent mutational
analyses for therapeutic purposes between April 2014 and December 2017 at the Pathology Unit and
were followed up at the Dermatologic Clinic of “Città della Salute e della Scienza” University Hospital
(Torino, Italy).
The study was conducted in accordance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans and within the guidelines and regulations
defined by the Research Ethics Committee of the University of Turin. This study was approved
by the Research Ethics Committee of the University of Turin (DSM-ChBU 5/2016). Considered the
retrospective nature of the research protocol and the lack of clinical impact on patient care, no specific
written informed consent had been required.
Clinical, epidemiological and histological data were collected from the medical history of
patients, whose tumours were diagnosed, treated and followed up according to previously reported
protocols [6,7,25].
At our institution, SLN biopsy (SLNB) has been performed since 1998 and the criteria adopted
for SLNB inclusion have been previously reported [13–15]. Age above 75 years and significant
comorbidities are exclusion criteria for this procedure. Moreover, due to the lack of specific guidelines,
in thick (>4 mm) melanomas [15,16], a multidisciplinary team discusses each case analysing the
risk/benefit ratio before proceeding with SLNB. All decisions are based upon the physicians’ experience
and clinical situation, considering that no evidence-based recommendations are available in this
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setting. All patients gave their written consent before undergoing ultrasound or CT scan to exclude the
presence of regional of distant metastases before SLNB or at diagnosis according to regional guidelines
(http://www.reteoncologica.it).
4.2. Mutational Status and TERT Promoter Assessment
Primary or metastatic tumour tissue sections were obtained for DNA extraction as previously
described [29]. Mutational detection was performed using the Sequenom MassARRAY® system
(Sequenom, San Diego, CA, USA) in conjunction with the Myriapod Colon Status kit that identifies
58, 54, 23 and 66 nucleotide substitutions in the KRAS, NRAS, BRAF and PIK3CA genes, respectively.
Mutant and wild type alleles were discriminated with the Sequenom MassARRAY® Analyser 4
platform. When warranted, the KIT mutational status was assessed by Sanger sequencing in BRAF
wild type samples (primary acral or mucosal lesions) [30]. Mutational status of the TERT core promoter
was determined in samples by PCR and Sanger sequencing between nucleotides −27 and −286
from the starting region (ATG) of the coding site, which includes the polymorphic site represented
by rs2853669.
In detail, we amplified the TERT promoter (located on chromosome 5) target region with a
touch-down PCR scheme using TaqGold 360 + GC enhancer (Applied Biosystems, Waltham, MA,
USA) and the following primer pair; TERT promoter forward 5′-CTCCCAGTGGATTCGCGGGC-3′
and reverse 5′-CCCACGTGCGCAGCAGGAC-3′, as described by Heidenreich et al. [31]. With 2%
agarose gel electrophoresis, we verified that the PCR products were of the expected size (260 bp) and
free of aspecific amplicons. PCR products were then purified and used as templates for the sequencing
reactions, which were performed in both directions (forward and reverse) with the same primers
using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems). After purification, the
sequences were analysed by Sanger direct sequencing using the ABI PRISM 3130 Genetic Analyzer
(Applied Biosystems), with the Sequencing Analysis 5.0 Software (Applied Biosystems). The two
most frequently identified variations within the TERT promoter gene region at positions 1295228 and
1295250 are known as C228T and C250T, respectively. These mutations are located at −124 and −146
bp upstream of the ATG start codon and were considered for analyses.
4.3. Statistical Analyses
All analyses were performed using Stata/MP 15.0 Statistical Software (STATA, College Station,
TX, USA). Continuous variables were summarised as the mean and standard deviation (SD), whereas
for categorical variables the frequency was provided. The patients’ characteristics were compared
using the chi-squared test for categorical variables and the T-test or ANOVA test for continuous
variables, according to Bonferroni corrections. Univariate/multivariate binary logistic regression
models were performed using progression to a visceral site as the dependent variable (yes or no)
and patient/tumour characteristics as covariates. Odds ratios and 95% CIs were estimated. The
Hosmer–Lemeshow goodness-of-fit statistics were used to determine whether the model adequately
described the data.
Disease-free interval (DFI) was calculated from the date of primary lesion diagnosis to the
date of tumour progression/recurrence or last follow-up. Survival curves between different groups
were plotted using the Kaplan–Meyer method and the statistical comparisons were performed with
log-rank test.
The final association (TERT promoter mutation and Trunk site towards visceral progression) has
been validated in an external independent cohort of primary melanoma patients.
5. Conclusions
Our findings encourage TERT mutation analysis at diagnosis in primary melanomas arising on
the trunk since they are more likely progress to visceral site. TERT screening would help in selecting
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patients who will potentially benefit from a more intensive follow-up protocol and a prompt initiation
of therapy.
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